Biosimilars in Europe
This reprint examines regulatory, pricing and reimbursement issues related to the market access and uptake of off-patent biologics, biosimilars, next-generation biologics and competing innovative medicines in European countries.
| Otros Autores: | , , |
|---|---|
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
[Place of publication not identified] :
MDPI - Multidisciplinary Digital Publishing Institute
2023.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009720241706719 |
Tabla de Contenidos:
- About the Editors vii
- Emerging Insights into European Markets of Biologics, Including Biosimilars 1
- Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009-2019 5
- Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria 21
- Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study 31
- Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany 39
- Barriers to Biosimilar Prescribing Incentives in the Context of Clinical Governance in Spain 59
- The Off-Patent Biological Market in Belgium: Is the Health System Creating a Hurdle to Fair Market Competition? 75
- Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices 81
- Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review 109
- Analysis of the Regulatory Science Applied to a Single Portfolio of Eight Biosimilar Product Approvals by Four Key Regulatory Authorities 127
- Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars 143
- Informing Patients about Biosimilar Medicines: The Role of European Patient Associations 157.
